About VyantBio
VyantBio is a company based in Cherry Hill (United States) founded in 1999. VyantBio has raised $10.5 million across 4 funding rounds from investors including National Science Foundation. The company has 25 employees as of December 31, 2022. VyantBio operates in a competitive market with competitors including Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others.
- Headquarter Cherry Hill, United States
- Employees 25 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vyant Bio, Inc.
-
Annual Revenue
$666 K (USD)-42as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.5 M (USD)
in 4 rounds
-
Latest Funding Round
$5.5 M (USD), Series A
Sep 14, 2016
- Investors
-
Employee Count
25
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of VyantBio
Unlock access to complete
Unlock access to complete
Funding Insights of VyantBio
VyantBio has successfully raised a total of $10.5M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.5 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in VyantBio
VyantBio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Locked | Locked | Locked |
Investor details for VyantBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VyantBio
Investment portfolio details for VyantBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - VyantBio
Detailed financials for VyantBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vyantbio Comparisons
Peer comparison for VyantBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of VyantBio
VyantBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Induced pluripotent stem cell-derived organoid models are developed for research.
|
|
| Locked | Locked | Locked |
Cell-based assays and 3D microtissues for drug screening are developed.
|
|
| Locked | Locked | Locked |
Regenerative medicine and 3D tissues are developed for therapeutic uses.
|
|
| Locked | Locked | Locked |
Developer of AI-based platform for lab-grown human tissues
|
|
| Locked | Locked | Locked |
Provider of computational tools for bacterial metabolomic and genomic data analysis
|
|
| Locked | Locked | Locked |
Scalable processes for organoid expansion are developed.
|
Detailed competitors of VyantBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vyantbio
Complete news archive for VyantBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VyantBio
VyantBio was founded in 1999 and raised its 1st funding round 8 years after it was founded.
VyantBio is headquartered in Cherry Hill, United States. It is registered at Cherry Hill, New Jersey, United States.
VyantBio is a funded company, having raised a total of $10.5M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at VyantBio is 25.
Annual revenue of VyantBio is $666K as on Dec 31, 2022.
Developer of drug discovery platform. The company has an AnalytiX platform to identify drug candidates, targets, and biomarkers with the help of human biology and machine learning. The company is developing human disease models and drugs for multiple diseases.
VyantBio's top competitors include Newcells Biotech, InSphero and Vivodyne.
VyantBio has 1 investor. Key investors include National Science Foundation.